Cargando…
Proteomic analysis of JAK2V617F-induced changes identifies potential new combinatorial therapeutic approaches
In excess of 90% of patients with polycythaemia vera (PV) express a mutated form of Janus kinase 2 (JAK2), JAK2V617F. Such aberrant proteins offer great potential for the treatment of these diseases; however, inhibitors to JAK2 have had limited success in the clinic in terms of curing the disease. T...
Autores principales: | Pearson, S, Williamson, A J K, Blance, R, Somervaille, T C P, Taylor, S, Azadbakht, N, Whetton, A D, Pierce, A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729335/ https://www.ncbi.nlm.nih.gov/pubmed/28533538 http://dx.doi.org/10.1038/leu.2017.143 |
Ejemplares similares
-
Erratum: Proteomic analysis of JAK2V617F-induced changes identifies potential new combinatorial therapeutic approaches
por: Pearson, S, et al.
Publicado: (2017) -
Identification of curaxin as a potential new therapeutic for JAK2 V617F mutant patients
por: Pearson, Stella, et al.
Publicado: (2023) -
AXL Inhibition Extinguishes Primitive JAK2 Mutated Myeloproliferative Neoplasm Progenitor Cells
por: Pearson, Stella, et al.
Publicado: (2019) -
JAK2V617F-Positive Endothelial Cells Induce Apoptosis and Release JAK2V617F-Positive Microparticles
por: Hekimoğlu, Hilal, et al.
Publicado: (2022) -
Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burden
por: Lee, A-Jin, et al.
Publicado: (2021)